GeoVax Presents Gedeptin Clinical Data At The AACR-AHNS Head And Neck Cancer Conference
Portfolio Pulse from Happy Mohamed
GeoVax Labs, Inc. (NASDAQ:GOVX) presented Phase 1/2 clinical trial data for its gene therapy candidate, Gedeptin, at the AACR-AHNS Head and Neck Cancer Conference. The ongoing trial is evaluating the safety and efficacy of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma. The study, funded in part by the FDA, has shown no serious adverse events and evidence of a reduction in tumor size. GeoVax anticipates completion of the trial by the end of 2023.
July 10, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeoVax Labs presented positive interim data from its ongoing Phase 1/2 clinical trial for Gedeptin, a gene therapy candidate for the treatment of head and neck squamous cell carcinoma. The trial is expected to be completed by the end of 2023.
The positive interim data from the ongoing Phase 1/2 clinical trial for Gedeptin could boost investor confidence in GeoVax Labs' pipeline. The fact that the trial is funded in part by the FDA and that Gedeptin has been granted orphan drug status for certain cancers could also be seen as positive indicators of the potential success of the therapy. However, the final impact on the company's stock price will depend on the completion of the trial and the subsequent steps towards commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100